features: Mild Cognitive Impairment

Phase III TRAILBLAZER-ALZ 2 trial: donanemab slows cognitive and functional decline in patients with early Alzheimer’s disease

Topline data has been released from Eli Lilly and Company showing that donanemab significantly slowed cognitive decline by 35% and…

Read More

Phase III EXERT trial: exercise shown to stall cognitive decline in patients with mild cognitive impairment

The Phase III, multicenter, randomized EXERT trial enrolled almost 300 patients to investigate the effects of regular exercise on brain…

Read More
The content of VJDementia is intended for healthcare professionals